Clinical significance of selective decline of donor-reactive IL-2-producing T lymphocytes after renal transplantation
UNSPECIFIED. (1997) Clinical significance of selective decline of donor-reactive IL-2-producing T lymphocytes after renal transplantation. TRANSPLANT IMMUNOLOGY, 5 (2). pp. 89-96. ISSN 0966-3274Full text not available from this repository.
Limiting dilution analysis technique was used to enumerate the circulating precursor frequency of donor and third-party-reactive helper T lymphocytes (HTLpf) in 28 renal allograft recipients before (pre-tx) and at three intervals (T1: 60-90 days, T2: 120-180 days, T3: 360-1620 days) after transplantation (post tr). Two patterns of responses were identified, in group 1 (n = 12),a five to 31-fold reduction of donor-reactive HTLpf (ranging from 1/19231-1/62500) occurred within 90-1620 days post-tx while in group 2 (n = 16), no significant changes of donor-reactive HTLpf were seen. In both groups, the third-party-reactive HTLpf in most of these patients remained largely unchanged throughout the study period. The number of HLA-DR mismatches, total number of rejection episodes, serum creatinine levels, and biopsy findings at T3 were compared in both groups using Fisher's exact probability, and the Mann-Whitney test. We found that 11 patients (92%) in group 1 were HLA-DR compatible with donors, while nine (56%) patients in group 2 were HLA-DR compatible with donors, p = 0.04. Ln group 1 eight rejection episodes occurred in five (41.6%) patients during the study period, compared to 33 in 13 (81%) patients in group 2,p = 0.03. Group 1 had a significantly lower serum creatinine level (at n); median: 136 vs 165 mu mol/l for group 2,p = 0.03. Biopsy indicated no rejection (at n) in eight (66%) patients in group 1 as compared to three (18%) patients in group 2,p = 0.03. Taken together, these results indicate that the frequency of circulating HTLpf correlate with the clinical status of the graft. Therefore monitoring of HTLpf in the peripheral blood could be useful in predicting graft outcome and selecting patients for reducing immunosuppression.
|Item Type:||Journal Article|
|Subjects:||Q Science > QR Microbiology > QR180 Immunology
R Medicine > RD Surgery
|Journal or Publication Title:||TRANSPLANT IMMUNOLOGY|
|Publisher:||ARNOLD, HODDER HEADLINE PLC|
|Number of Pages:||8|
|Page Range:||pp. 89-96|
Actions (login required)